Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Froudarakis ME (2012) Pleural effusion in lung cancer: more questions than answers. Respiration 83(5):367–376. https://doi.org/10.1159/000338169

Article  PubMed  Google Scholar 

Johnston WW (1985) The malignant pleural effusion: A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 56(4):905–909. https://doi.org/10.1002/1097-0142(19850815)56:4%3C905::AID-CNCR2820560435%3E3.0.CO;2-U

Article  CAS  PubMed  Google Scholar 

Antunes G, Neville E, Duffy J, Ali N, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society (2003) BTS guidelines for the management of malignant pleural effusions. Thorax 58(Suppl 2):ii29–ii38. https://doi.org/10.1136/thorax.58.suppl_2.ii29

Article  PubMed  PubMed Central  Google Scholar 

Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R (2012) Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thor Oncol 7(10):1485–1489. https://doi.org/10.1097/JTO.0b013e318267223a

Article  Google Scholar 

Epaillard N, Benitez JC, Gorria T, Fabre E, Riudavets M, Reyes R, Planchard D, Oudard S, Viñolas N, Reguart N, Besse B, Mezquita L, Auclin E (2021) Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): the pluie study. Lung cancer (Amsterdam, Netherlands) 155:114–119. https://doi.org/10.1016/j.lungcan.2021.03.015

Article  CAS  PubMed  Google Scholar 

Jiang L, Li P, Gong Z, Hu B, Ma J, Wang J, Chu H, Zhang L, Sun P, Chen J (2016) Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res 36(3):1313–1318

CAS  PubMed  Google Scholar 

Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K, North East Japan Study Group (2016) A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer (Amsterdam, Netherlands) 99:131–136. https://doi.org/10.1016/j.lungcan.2016.07.003

Article  PubMed  Google Scholar 

Noro, R., Kobayashi, K., Usuki, J., Yomota, M., Nishitsuji, M., Shimokawa, T., Ando, M., Hino, M., Hagiwara, K., Miyanaga, A., Seike, M., Kubota, K., Gemma, A., & North East Japan Study group (2020) Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: a phase II study North East Japan Study group trial NEJ013B. Thora Cancer 11(7):1876–1884. https://doi.org/10.1111/1759-7714.13472

Article  CAS  Google Scholar 

Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T (2021) Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Invest New Drugs 39(4):1106–1112. https://doi.org/10.1007/s10637-021-01076-8

Article  CAS  PubMed  Google Scholar 

Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718. https://doi.org/10.1634/theoncologist.12-6-713

Article  CAS  PubMed  Google Scholar 

Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K (2022) The effect of pleural effusion on prognosis in patients with non-small cell lung cancer undergoing immunochemotherapy: a retrospective observational study. Cancers 14(24):6184. https://doi.org/10.3390/cancers14246184

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabang RL, Gandhiraj D, Fanucchi M, Epelbaum O (2018) Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med 12(2):87–94. https://doi.org/10.1080/17476348.2018.1417042

Article  CAS  PubMed  Google Scholar 

Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A et al (2020) Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opin Biol Ther 20(3):319–326. https://doi.org/10.1080/14712598.2020.1724953

Article  CAS  PubMed  Google Scholar 

Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T (2020) Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest New Drugs 38(1):211–218. https://doi.org/10.1007/s10637-019-00882-5

Article  CAS  PubMed  Google Scholar 

Kawachi H, Tamiya M, Taniguchi Y, Yokoyama T, Yokoe S, Oya Y, Imaji M, Okabe F, Kanazu M, Sakata Y, Uematsu S, Tanaka S, Arai D, Saito G, Kobe H, Miyauchi E, Okada A, Hara S, Kumagai T (2022) Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with malignant pleural effusion: A retrospective multicenter cohort study. JTO Clin Res Rep 3(7):100355. https://doi.org/10.1016/j.jtocrr.2022.100355

Article  PubMed  PubMed Central  Google Scholar 

Nakagawa N, Kawakami M (2022) Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. Front Oncol 12:952393. https://doi.org/10.3389/fonc.2022.952393

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J et al (2022) Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(5):497–530. https://doi.org/10.6004/jnccn.2022.0025

Article  PubMed  Google Scholar 

Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N (2014) The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion. Indian J Cancer 51(Suppl 3):e82–e85. https://doi.org/10.4103/0019-509X.154058

Article  PubMed  Google Scholar 

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242–1251. https://doi.org/10.1634/theoncologist.2009-0109

Article  CAS  PubMed  Google Scholar 

Valecha GK, Vennepureddy A, Ibrahim U, Safa F, Samra B, Atallah JP (2017) Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Rev Anticancer Ther 17(1):47–59. https://doi.org/10.1080/14737140.2017.1259574

Article  CAS  PubMed  Google Scholar 

Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C (2020) Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition. Sci Rep 10(1):5784. https://doi.org/10.1038/s41598-020-62813-2

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, Graupner V, Sun SW, Hoang T, Jessop H, McCleland M, Ballinger M, Sandler A, Socinski MA (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III Trial. J Thorac Oncol 15(8):1351–1360. https://doi.org/10.1016/j.jtho.2020.03.028

Article  CAS  PubMed  Google Scholar 

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(7):924–937. https://doi.org/10.1016/S1470-2045(19)30167-6

Article  CAS  PubMed  Google Scholar 

Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY (2015) BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33(19):2197–2204. https://doi.org/10.1200/JCO.2014.59.4424

Article  CAS  PubMed  Google Scholar 

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. https://doi.org/10.1056/NEJMoa061884

Article  CAS  PubMed  Google Scholar 

Yu H, Chen P, Xia L, Fu S, Chen C, Zhang X, He L, Zhang B, Zhou Y, Hong S (2021) PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer. J Immunother Cancer 9(11):e003431. https://doi.org/10.1136/jitc-2021-003431

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Yang Y, Yu J, Zhang S, Li X, Wu X, Nie X, Liu W, Zhang P, Li Y, Li A, Ai B (2022) Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thoracic cancer 13(3):322–337. https://doi.org/10.1111/1759-7714.14244

Article  CAS  PubMed  Google Scholar 

Liu T, Ding S, Dang J, Wang H, Chen J, Li G (2019) First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. J Thorac Dis 11(7):2899–2912.